Serum BCL2/IGH DNA in follicular lymphoma patients: A minimal residual disease marker

Christopher Gocke, M. S. Kopreski, F. A. Benko, L. Sternas, L. W. Kwak

Research output: Contribution to journalArticle

Abstract

The majority of follicular lymphoma patients carry a t(14;18) juxtaposing the BCL2 oncogene to the immunoglobulin heavy chain joining region (IgH). Molecular analysis for follicular lymphoma-specific DNA translocations may permit evaluation of minimal residual disease (MRD). We identify extracellular BCL2/IGH transgene DNA in the serum of patients with follicular lymphoma, and evaluate its utility as a surrogate marker. DNA was harvested from both the sera and bone marrow of 5 stage IV follicular lymphoma patients prior to and after chemotherapy and following a novel vaccine-based regimen. Serial PCR amplifications were performed using heminested BCL2-specific major breakpoint cluster region (MBR) primers and the immunoglobulin heavy chain consensus primer. Amplification products were detected by agarose gel electrophoresis, and comparison was made to amplification products from the original tumor biopsy. Results show that four of the five lymphoma patients carried extracellular BCL2/IGH transgene DNA in their serum. The remaining patient did not have an amplification product from either the tumor or the serum, suggesting either the absence of a translocation or the presence of a variant translocation not detectable with this primer set. Transgene DNA was detectable in serum even in patients with MRD, comparing favorably with bone marrow results. In at least one patient, the presence of the transgene in serum at the conclusion of therapy preceded relapse. In conclusion, it seems that tumor-specific, extracellular DNA is present in the serum of follicular lymphoma patients, including those with MRD. Because extracellular DNA may be released into the bloodstream by tumor throughout the body it may be less subject to sampling error, and appears to be an ideal surrogate marker.

Original languageEnglish (US)
Pages (from-to)165-172
Number of pages8
JournalLeukemia and Lymphoma
Volume39
Issue number1-2
StatePublished - 2000
Externally publishedYes

Fingerprint

Follicular Lymphoma
Residual Neoplasm
DNA
Serum
Transgenes
Immunoglobulin Heavy Chains
Neoplasms
Biomarkers
Bone Marrow
Agar Gel Electrophoresis
Selection Bias
Oncogenes
Lymphoma
Vaccines
Biopsy
Recurrence
Drug Therapy
Polymerase Chain Reaction

Keywords

  • BCL2
  • Extracellular DNA
  • Follicular lymphoma
  • Minimal residual disease
  • PCR
  • Surrogate marker

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Gocke, C., Kopreski, M. S., Benko, F. A., Sternas, L., & Kwak, L. W. (2000). Serum BCL2/IGH DNA in follicular lymphoma patients: A minimal residual disease marker. Leukemia and Lymphoma, 39(1-2), 165-172.

Serum BCL2/IGH DNA in follicular lymphoma patients : A minimal residual disease marker. / Gocke, Christopher; Kopreski, M. S.; Benko, F. A.; Sternas, L.; Kwak, L. W.

In: Leukemia and Lymphoma, Vol. 39, No. 1-2, 2000, p. 165-172.

Research output: Contribution to journalArticle

Gocke, C, Kopreski, MS, Benko, FA, Sternas, L & Kwak, LW 2000, 'Serum BCL2/IGH DNA in follicular lymphoma patients: A minimal residual disease marker', Leukemia and Lymphoma, vol. 39, no. 1-2, pp. 165-172.
Gocke, Christopher ; Kopreski, M. S. ; Benko, F. A. ; Sternas, L. ; Kwak, L. W. / Serum BCL2/IGH DNA in follicular lymphoma patients : A minimal residual disease marker. In: Leukemia and Lymphoma. 2000 ; Vol. 39, No. 1-2. pp. 165-172.
@article{56786fde44c441a28b314864098e751d,
title = "Serum BCL2/IGH DNA in follicular lymphoma patients: A minimal residual disease marker",
abstract = "The majority of follicular lymphoma patients carry a t(14;18) juxtaposing the BCL2 oncogene to the immunoglobulin heavy chain joining region (IgH). Molecular analysis for follicular lymphoma-specific DNA translocations may permit evaluation of minimal residual disease (MRD). We identify extracellular BCL2/IGH transgene DNA in the serum of patients with follicular lymphoma, and evaluate its utility as a surrogate marker. DNA was harvested from both the sera and bone marrow of 5 stage IV follicular lymphoma patients prior to and after chemotherapy and following a novel vaccine-based regimen. Serial PCR amplifications were performed using heminested BCL2-specific major breakpoint cluster region (MBR) primers and the immunoglobulin heavy chain consensus primer. Amplification products were detected by agarose gel electrophoresis, and comparison was made to amplification products from the original tumor biopsy. Results show that four of the five lymphoma patients carried extracellular BCL2/IGH transgene DNA in their serum. The remaining patient did not have an amplification product from either the tumor or the serum, suggesting either the absence of a translocation or the presence of a variant translocation not detectable with this primer set. Transgene DNA was detectable in serum even in patients with MRD, comparing favorably with bone marrow results. In at least one patient, the presence of the transgene in serum at the conclusion of therapy preceded relapse. In conclusion, it seems that tumor-specific, extracellular DNA is present in the serum of follicular lymphoma patients, including those with MRD. Because extracellular DNA may be released into the bloodstream by tumor throughout the body it may be less subject to sampling error, and appears to be an ideal surrogate marker.",
keywords = "BCL2, Extracellular DNA, Follicular lymphoma, Minimal residual disease, PCR, Surrogate marker",
author = "Christopher Gocke and Kopreski, {M. S.} and Benko, {F. A.} and L. Sternas and Kwak, {L. W.}",
year = "2000",
language = "English (US)",
volume = "39",
pages = "165--172",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Serum BCL2/IGH DNA in follicular lymphoma patients

T2 - A minimal residual disease marker

AU - Gocke, Christopher

AU - Kopreski, M. S.

AU - Benko, F. A.

AU - Sternas, L.

AU - Kwak, L. W.

PY - 2000

Y1 - 2000

N2 - The majority of follicular lymphoma patients carry a t(14;18) juxtaposing the BCL2 oncogene to the immunoglobulin heavy chain joining region (IgH). Molecular analysis for follicular lymphoma-specific DNA translocations may permit evaluation of minimal residual disease (MRD). We identify extracellular BCL2/IGH transgene DNA in the serum of patients with follicular lymphoma, and evaluate its utility as a surrogate marker. DNA was harvested from both the sera and bone marrow of 5 stage IV follicular lymphoma patients prior to and after chemotherapy and following a novel vaccine-based regimen. Serial PCR amplifications were performed using heminested BCL2-specific major breakpoint cluster region (MBR) primers and the immunoglobulin heavy chain consensus primer. Amplification products were detected by agarose gel electrophoresis, and comparison was made to amplification products from the original tumor biopsy. Results show that four of the five lymphoma patients carried extracellular BCL2/IGH transgene DNA in their serum. The remaining patient did not have an amplification product from either the tumor or the serum, suggesting either the absence of a translocation or the presence of a variant translocation not detectable with this primer set. Transgene DNA was detectable in serum even in patients with MRD, comparing favorably with bone marrow results. In at least one patient, the presence of the transgene in serum at the conclusion of therapy preceded relapse. In conclusion, it seems that tumor-specific, extracellular DNA is present in the serum of follicular lymphoma patients, including those with MRD. Because extracellular DNA may be released into the bloodstream by tumor throughout the body it may be less subject to sampling error, and appears to be an ideal surrogate marker.

AB - The majority of follicular lymphoma patients carry a t(14;18) juxtaposing the BCL2 oncogene to the immunoglobulin heavy chain joining region (IgH). Molecular analysis for follicular lymphoma-specific DNA translocations may permit evaluation of minimal residual disease (MRD). We identify extracellular BCL2/IGH transgene DNA in the serum of patients with follicular lymphoma, and evaluate its utility as a surrogate marker. DNA was harvested from both the sera and bone marrow of 5 stage IV follicular lymphoma patients prior to and after chemotherapy and following a novel vaccine-based regimen. Serial PCR amplifications were performed using heminested BCL2-specific major breakpoint cluster region (MBR) primers and the immunoglobulin heavy chain consensus primer. Amplification products were detected by agarose gel electrophoresis, and comparison was made to amplification products from the original tumor biopsy. Results show that four of the five lymphoma patients carried extracellular BCL2/IGH transgene DNA in their serum. The remaining patient did not have an amplification product from either the tumor or the serum, suggesting either the absence of a translocation or the presence of a variant translocation not detectable with this primer set. Transgene DNA was detectable in serum even in patients with MRD, comparing favorably with bone marrow results. In at least one patient, the presence of the transgene in serum at the conclusion of therapy preceded relapse. In conclusion, it seems that tumor-specific, extracellular DNA is present in the serum of follicular lymphoma patients, including those with MRD. Because extracellular DNA may be released into the bloodstream by tumor throughout the body it may be less subject to sampling error, and appears to be an ideal surrogate marker.

KW - BCL2

KW - Extracellular DNA

KW - Follicular lymphoma

KW - Minimal residual disease

KW - PCR

KW - Surrogate marker

UR - http://www.scopus.com/inward/record.url?scp=0033846852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033846852&partnerID=8YFLogxK

M3 - Article

C2 - 10975396

AN - SCOPUS:0033846852

VL - 39

SP - 165

EP - 172

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -